End-of-day quote
Taiwan S.E.
23:00:00 16/05/2024 BST
|
5-day change
|
1st Jan Change
|
96.2
TWD
|
+2.34%
|
|
+4.57%
|
-5.69%
|
Fiscal Period: December |
2019
|
2020
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
4,144
|
5,085
|
8,839
|
12,266
|
11,569
|
-
|
Enterprise Value (EV)
1 |
7,188
|
5,085
|
8,839
|
12,266
|
13,141
|
12,810
|
P/E ratio
|
349
x
|
13.6
x
|
21.7
x
|
97.1
x
|
16.4
x
|
-
|
Yield
|
-
|
-
|
-
|
-
|
2.05%
|
5.47%
|
Capitalization / Revenue
|
1.5
x
|
1.65
x
|
-
|
2.82
x
|
2.34
x
|
2.03
x
|
EV / Revenue
|
2.6
x
|
1.65
x
|
-
|
2.82
x
|
2.66
x
|
2.25
x
|
EV / EBITDA
|
17.6
x
|
-
|
-
|
8.52
x
|
9.14
x
|
6.78
x
|
EV / FCF
|
-6,388,125
x
|
-
|
-
|
-
|
-
|
22,591,929
x
|
FCF Yield
|
-0%
|
-
|
-
|
-
|
-
|
0%
|
Price to Book
|
0.95
x
|
-
|
-
|
-
|
1.5
x
|
1.36
x
|
Nbr of stocks (in thousands)
|
99,013
|
108,313
|
120,256
|
120,256
|
120,256
|
-
|
Reference price
2 |
41.85
|
46.95
|
73.50
|
102.0
|
96.20
|
96.20
|
Announcement Date
|
29/03/20
|
04/03/21
|
15/03/23
|
12/03/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
2,760
|
3,075
|
-
|
4,346
|
4,934
|
5,689
|
EBITDA
1 |
408.8
|
-
|
-
|
1,439
|
1,438
|
1,889
|
EBIT
1 |
24.44
|
-
|
-
|
971.7
|
915
|
1,325
|
Operating Margin
|
0.89%
|
-
|
-
|
22.36%
|
18.54%
|
23.29%
|
Earnings before Tax (EBT)
1 |
-40.21
|
-
|
-
|
299
|
1,085
|
-
|
Net income
1 |
11.63
|
-
|
409.4
|
126.2
|
706
|
-
|
Net margin
|
0.42%
|
-
|
-
|
2.9%
|
14.31%
|
-
|
EPS
2 |
0.1200
|
3.460
|
3.390
|
1.050
|
5.870
|
-
|
Free Cash Flow
|
-1,125
|
-
|
-
|
-
|
-
|
567
|
FCF margin
|
-40.78%
|
-
|
-
|
-
|
-
|
9.97%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
30.02%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
1.970
|
5.260
|
Announcement Date
|
29/03/20
|
04/03/21
|
15/03/23
|
12/03/24
|
-
|
-
|
Fiscal Period: December |
2022 Q1
|
2022 Q2
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
834.9
|
838.2
|
932
|
1,087
|
-
|
1,129
|
1,198
|
1,144
|
1,348
|
1,308
|
EBITDA
|
-
|
-
|
253.4
|
274.4
|
-
|
272.2
|
-
|
-
|
-
|
-
|
EBIT
1 |
-50.56
|
6.319
|
134.2
|
157.6
|
-
|
147.9
|
532
|
183
|
292
|
251
|
Operating Margin
|
-6.06%
|
0.75%
|
14.4%
|
14.5%
|
-
|
13.1%
|
44.4%
|
16%
|
21.66%
|
19.19%
|
Earnings before Tax (EBT)
|
-
|
-
|
-25.62
|
99.83
|
-
|
-99.77
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-25.16
|
83.38
|
-
|
-114.6
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-2.7%
|
7.67%
|
-
|
-10.14%
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-
|
-0.2100
|
0.6900
|
0.4800
|
-0.9500
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
13/05/22
|
12/08/22
|
12/05/23
|
10/08/23
|
10/08/23
|
10/11/23
|
12/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
3,045
|
-
|
-
|
-
|
1,572
|
1,241
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
7.447
x
|
-
|
-
|
-
|
1.093
x
|
0.657
x
|
Free Cash Flow
|
-1,125
|
-
|
-
|
-
|
-
|
567
|
ROE (net income / shareholders' equity)
|
0.27%
|
-
|
-
|
-
|
5.1%
|
12.4%
|
ROA (Net income/ Total Assets)
|
0.13%
|
-
|
-
|
-
|
2.5%
|
7.5%
|
Assets
1 |
9,158
|
-
|
-
|
-
|
28,240
|
-
|
Book Value Per Share
2 |
44.10
|
-
|
-
|
-
|
64.20
|
71.00
|
Cash Flow per Share
2 |
2.930
|
-
|
-
|
-
|
8.820
|
-
|
Capex
1 |
1,415
|
-
|
-
|
-
|
777
|
777
|
Capex / Sales
|
51.28%
|
-
|
-
|
-
|
15.75%
|
13.66%
|
Announcement Date
|
29/03/20
|
04/03/21
|
15/03/23
|
12/03/24
|
-
|
-
|
Last Close Price
96.2
TWD Average target price
135
TWD Spread / Average Target +40.33% Consensus |
1st Jan change
|
Capi.
|
---|
| -5.69% | 359M | | +32.09% | 693B | | +29.39% | 584B | | -1.34% | 372B | | +20.34% | 332B | | +7.39% | 294B | | +14.25% | 239B | | -3.03% | 211B | | +10.02% | 210B | | +8.49% | 168B |
Other Pharmaceuticals
|